Skip to main content
Clinical Trials/NCT04864431
NCT04864431UnknownNot Applicable

The Effect of Vitamin D on Factors Contributing Pre Cachexia and Cachexia, a Study on Epithelial Ovarian Cancer

Indonesia University6 sites in 1 country54 target enrollmentStarted: January 12, 2022Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
54
Locations
6
Primary Endpoint
Rate of immune response in participants receiving vitamin D change from baseline as assessed by lymphocyte CD8

Study Overview

Brief Summary

Several ex vivo, in vitro, and observational studies on various type of cancer shown positive effect of vitamin D. Vitamin D has widely known as immunomodulator property in various diseases. However, it remains limited studies on immunity and cachexia in cancer, particularly in ovarian cancer. This study will investigate the effect of vitamin D in immune response during chemotherapy among epithelial ovarian cancer patients who have a low level of vitamin D and cachexia

Detailed Description

Studies result from laboratory suggested that vitamin D inhibit cancer cell proliferation and upregulate apoptosis pathway. Data from observational and ecology studies showed the inverse relationship between level of vitamin D and cancer risk. Clinical trials on colorectal, prostate, and breast cancer suggested that vitamin D had positive effect and improved clinical markers.

Vitamin D may alter immune response through regulation on cytotoxic CD8 T-lymphocyte and reduce pro inflammatory cytokines. High level of interleukin-6 and other cytokines in cancer may decrease lymphocyte T activity, resulting lowering effect of immune response.

This clinical trial will enroll 54 adults with newly diagnosed epithelial ovarian cancer patients. Following receive of informed consent, they will randomly allocated to receive whether vitamin D 2000 IU or placebo during chemotherapy period (6 cycles).

Subjects will fill out questionnaire on their first visit as well as each chemotherapy cycle (each month). Questionnaire will ask about demographic data, meal intake, sun exposure, and cachexia questionnaire (based on Cachexia Score). Subjects will also be examined on their physical status, anthropometry (weight, height, waist circumference), as well as body composition (fat mass, fat free mass, fat free mass index, phase angle).

Blood samples will be drawn from peripheral vein and sent to National Cancer Referral Hospital laboratory to measure 25(OH)D level, interleukin-6, CD8 cytotoxic level, CD8 cytotoxic activity, and circulating tumor cells. Blood collection will be done on the first visit, 3rd cycle of chemotherapy, and last cycle of chemotherapy. Subjects will be given their samples result during follow-up visit.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Investigator)

Masking Description

Neither do investigator nor participants will not know the random allocation

Eligibility Criteria

Ages
18 Years to 60 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • age 18-60 years old who are newly diagnosed with ovarian cancer based on histopathology
  • epithelial ovarian cancer stage II-III
  • haven't received chemotherapy
  • pre-cachexia or cachexia
  • level of vitamin D below 30 ng/ml
  • no vitamin D allergy
  • ability and willingness to understand and provide informed consent

Exclusion Criteria

  • autoimmune disease
  • chronic liver disease
  • chronic renal disease
  • known had hypercalcemia
  • refractory cachexia

Outcomes

Primary Outcomes

Rate of immune response in participants receiving vitamin D change from baseline as assessed by lymphocyte CD8

Time Frame: 6 months

lymphocyte CD8 is measured by flowcytometry

Secondary Outcomes

  • Find the change of vitamin D level(6 month)
  • Find the rate of sun exposure(1 week)
  • Find the daily intake of vitamin D from food(1 month)
  • Effect of vitamin D in lowering inflammation(6 months)
  • Effect of vitamin D in lowering circulation tumor cells (CTC)(6 months)
  • Effect of vitamin D in improving staging of cachexia(6 month)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

dr. Nurul Ratna Mutu Manikam, M.Gizi., Sp.GK

Principle Investigator

Indonesia University

Study Sites (6)

Loading locations...

Similar Trials